Comprehensive Financial Management LLC Reduces Stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Comprehensive Financial Management LLC lowered its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 97.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 17,656 shares of the company’s stock after selling 688,646 shares during the period. Comprehensive Financial Management LLC’s holdings in Ginkgo Bioworks were worth $144,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of DNA. Russell Investments Group Ltd. lifted its holdings in Ginkgo Bioworks by 9,440.6% during the first quarter. Russell Investments Group Ltd. now owns 31,961 shares of the company’s stock valued at $37,000 after purchasing an additional 31,626 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. raised its position in shares of Ginkgo Bioworks by 644.5% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 32,319 shares of the company’s stock valued at $263,000 after purchasing an additional 27,978 shares during the period. Verition Fund Management LLC purchased a new stake in shares of Ginkgo Bioworks during the 3rd quarter valued at approximately $792,000. Algert Global LLC bought a new position in Ginkgo Bioworks in the 2nd quarter worth approximately $36,000. Finally, Wellington Wealth Strategies LLC. purchased a new position in Ginkgo Bioworks in the 2nd quarter valued at approximately $41,000. Institutional investors own 78.63% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on DNA shares. TD Cowen raised their price target on Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, September 20th. BTIG Research raised their target price on Ginkgo Bioworks from $0.20 to $7.00 and gave the stock a “sell” rating in a research note on Friday, August 23rd. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $4.58.

Ginkgo Bioworks Stock Performance

Ginkgo Bioworks stock opened at $8.70 on Monday. The stock has a market capitalization of $500.07 million, a PE ratio of -0.67 and a beta of 1.09. The business’s 50-day simple moving average is $7.93. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $5.26 and a 52 week high of $75.20.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.